drugset
drugset / Trial / NCT02540668

A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants

NCT02540668 ↗

Phase 1 Completed 15 enrolled AstraZeneca Eli Lilly and Company · collab
Non-randomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to look at how much warfarin gets into the blood stream and how long it takes the body to get rid of it when given both with and without lanabecestat. Another purpose is to evaluate the effectiveness of warfarin therapy to prevent blood clots when given with lanabecestat by measuring international normalized ratio (INR). INR measures the time it takes for blood to clot and compares it to an average. Information about any side effects that may occur will also be collected. The study will last about 5 weeks from the first dose to follow-up for each participant.

Timeline

Start
2015-09-30
Primary completion
2016-01-31
Completion
2016-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Lanabecestat Small molecule — Oral
Subject Warfarin Small molecule 15 mg Oral

Indications

No indication recorded.